Clinical question:What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?/Table
From Cancer Guidelines Wiki
Table - Summary of five randomised trials included in the LACE meta-analysis
| Author | Name | N/n | Age | ECOG | Sx | Regime, % completing
Planned cycles |
OS
HR.95% CI |
OS stage II
HR,95% CI | |
|---|---|---|---|---|---|---|---|---|---|
| Winton T et al 2005[1] | NCIC-CTG JBR10 | 482/ 265 | 61
(34-78) |
0,1 | 91% | Cisplatin/ VRL x 4 | 50% | 0.69,
0.52-0.91, p=0.009 |
0.59,
(0.42-0.85) p=0.004 |
| Arriagada R et al 2010[2] | IALT | 1867/ 452 | 59
(22-77) |
0, 1, 2 | 99% | Platinum based x 3-4 | *73.8% | #0.91,
0.81-1.02, p=0.10 |
0.92,
(0.73-1.15) p=0.22 |
| Douillard et al 2006[3] | ANITA | 840/ 203 | 59
(18-75) |
0,1,2 | 95% | Cisplatin/ VRL x 4 | 50% | 0.80,
0.66-0.96, P=0.017 |
0.71,
(0.49-1.03) |
| Scagliotti et al 2003 [4] | ALIPI | 1209/ 355 | 61
(33-76) |
N/A | N/A | MVP X 3 | 69% | 0.96,
0.81-1.13 p=0.589 |
0.78,
(0.60-1.03) |
| Waller et al 2004[5] | Big Lung Trial (BLT) | 381/ 145 | 61 | 0,1,2 | ** 86% | Platinum based x 3 | 64% | 1.02,
0.77-1.35 p=0.9 |
NS |
- Key
- N/n – Total number of patients/Number of patients with stage II disease
- Sx - Percentage of patients who had Pneumonectomy/ Lobectomy
- OS Overall survival
- N/A- Not available
- VRL- Vinorelbine, MVP- Mitomycin C, Vinblastine, Prednisolone
- # Long term follow up results
- ** Reported as complete resection (R0)
- * Defined by at least 240 mg of Cisplatin
References
<references>